Literature DB >> 10362434

Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project.

A J Rush1, W V Rago, M L Crismon, M G Toprac, S P Shon, T Suppes, A L Miller, M H Trivedi, A C Swann, M M Biggs, K Shores-Wilson, T M Kashner, T Pigott, J A Chiles, D A Gilbert, K Z Altshuler.   

Abstract

This article provides an overview of the issues involved in developing, using, and evaluating specific medication guidelines for patients with psychiatric disorders. The potential advantages and disadvantages, as well as the essential elements in the structure of algorithms, are illustrated by experience to date with the Texas Medication Algorithm Project, a public-academic collaboration. Phase 1 entailed assembling research findings on the efficacy of medications for schizophrenic, bipolar, and major depressive disorders. This knowledge was evaluated for its quality and relevance, integrated with expert clinical judgment as well as input by practicing clinicians, family advocates, and patients. Phase 1 (the design and development of the algorithms) was followed by a feasibility test (Phase 2). Phase 3 is an ongoing evaluation comparing the clinical and economic effects of using specific medication guidelines (algorithms) versus treatment as usual in public sector patients with severe and persistent mental illnesses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362434     DOI: 10.4088/jcp.v60n0503

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

2.  Customizing treatment to the patient: adaptive treatment strategies.

Authors:  Susan A Murphy; L M Collins; A John Rush
Journal:  Drug Alcohol Depend       Date:  2007-03-09       Impact factor: 4.492

3.  [Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].

Authors:  G Juckel; K Stahl; C Norra
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

Review 4.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 5.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

6.  Do comprehensive, coordinated, recovery-oriented services alter the pattern of use of treatment services? Mental health treatment study impacts on SSDI beneficiaries' use of inpatient, emergency, and crisis services.

Authors:  David Salkever; Brent Gibbons; Xiaotao Ran
Journal:  J Behav Health Serv Res       Date:  2014-10       Impact factor: 1.505

7.  Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia.

Authors:  Kathy Shores-Wilson; Melanie M Biggs; Alexander L Miller; Thomas J Carmody; John A Chiles; A John Rush; M Lynn Crismon; Marcia G Toprac; Bradley P Witte; Joe C Webster
Journal:  Int J Methods Psychiatr Res       Date:  2002       Impact factor: 4.035

8.  [Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison].

Authors:  B Janssen; S Weinmann; M Berger; M Härter; T Held; M Leipert; H J Luderer; M Schwarz; T Steinert; W Gaebel
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

9.  Preparing to implement medication algorithms: staff perspectives and system infrastructure.

Authors:  Jennifer P Wisdom; Sarann Bielavitz; Bentson McFarland; Jon C Collins; Ann Hamer; Dean Haxby; David A Pollack
Journal:  J Psychiatr Pract       Date:  2008-07       Impact factor: 1.325

10.  Midline and right frontal brain function as a physiologic biomarker of remission in major depression.

Authors:  Ian A Cook; Aimee M Hunter; Michelle Abrams; Barbara Siegman; Andrew F Leuchter
Journal:  Psychiatry Res       Date:  2009-10-22       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.